We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers should make use of risk-based thinking to help prevent “catastrophic failures,” said quality expert Amanda McPharland in a June 14 WCG FDAnews webinar. Read More
Panelists said that there are no currently approved targeted therapies and there exists a dire patient need for treatments, they were troubled by Ipsen’s pivotal late-stage study data. Read More
The FDA’s final guidance on developing drugs and biologics to treat chronic rhinosinusitis with nasal polyps shares considerations sponsors should make for trial design/population, safety, effectiveness, and statistical analysis. Read More
The FTC and the DOJ are pushing for rules that would require companies planning a merger or acquisition to forestall consummation until federal agencies have had enough time to more deeply investigate whether the transaction would violate antitrust laws and “harm the American public.” Read More
An FDA advisory committee voted 10 to 4 to recommend Ipsen Biopharmaceuticals’ palovarotene as an effective therapy for the ultra-rare bone disease fibrodysplasia ossificans progressiva (FOP), which causes tendons and ligaments to be replaced by bone. Read More
The FDA’s interpretation and policies on exemption as well as prohibition of wholesaling of compounded drugs in section 503B of the Food, Drug & Cosmetic Act (FDC) are explained in a draft guidance published on June 27. Read More
Receiving oncology study submissions that propose a too-wide range of types and formats of real world data (RWD) — along with a lack of basic elements of study design — has prompted the creation of the FDA’s new Oncology Quality, Characterization, and Assessment of Real-world Data (QCARD) Initiative. Read More
When communicating about the efficacy and risks of prescription and OTC drugs directly to consumers, quantitative information “can improve consumers’ accuracy in estimating the drug’s benefits and risks” and should be “accurate and understandable” says the FDA in a final guidance issued Tuesday. Read More
There’s a need to tap into a greater array of data sources, identify and consider research questions earlier on, and speed up the generation of real-world evidence (RWE), according to a report from the EMA released Monday. Read More
I am good friends with a woman with Parkinson’s disease. When I see her, I feel grateful that this is the most exciting time in history for medical advancements. The drugs she is taking clearly are extending her good “on” time so that she has extended periods during the day when she can function with daily activities. I also have seen the difference between good “on” time and “off” time, when the medications start wearing off. Read More